03 April 2002 19:44 [Source: ICIS news]
HOUSTON (CNI)--Isis Pharmaceuticals announced Wednesday the issuance of a new US patent to the University of Massachusetts and said the patent strengthens the antisense technology that Isis licenses from the university.
Carlsbad, California-based Isis said the newly issued patent "covers antisense drugs that use a broad range of second-generation antisense chemistries." Isis uses those second-generation chemistries to create antisense drugs that are said to have greater efficacy and fewer side effects.
Isis said in a statement: "As a licensee of this patent, Isis' opportunity to create highly specific antisense drugs for a broad range of diseases is further enhanced and protected."
Lynne Parshall, Isis chief financial officer and executive vice president, said: "Control of this patent further supports the commercialisation of second-generation antisense drugs, which are increasingly valued by the pharmaceutical industry."
"Our strategy," he said, "is to facilitate the development of more antisense drugs than we can afford to develop on our own. Our intellectual property estate is a key asset in the implementation of this strategy."
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|